Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX)
Q3 2016 Earnings Call
November 02, 2016 9:00 am ET
Administrators
Jessica Cho - Pacira Pharmaceuticals, Inc.
David M. Stack - Pacira Pharmaceuticals, Inc.
James S. Scibetta - Pacira Pharmaceuticals, Inc.
Charles A. Reinhart - Pacira Pharmaceuticals, Inc.
Scott N. Braunstein - Pacira Pharmaceuticals, Inc.
Investigators
David A. Amsellem - Piper Jaffray and Co.
Donald Bruce Ellis - JMP Securities LLC
Douglas Tsao - Barclays Capital, Inc.
Administrator
Much obliged to you for joining the Pacira Pharmaceuticals Third Quarter 2016 Financial Results Conference Call. Right now, all members are in a listen-just mode. Taking after the formal comments, the Pacira administration group will open the lines for a question-and-answer period. If you don't mind be exhorted that this call is being recorded at the organization's demand and will be filed on the organization's site for two weeks from today's date.
As of now, I might want to present Jessica Cho of Pacira Pharmaceuticals. Ma'am, you may start.
Jessica Cho - Pacira Pharmaceuticals, Inc.
Hello, everybody. The configuration of this call will be as per the following: Dave Stack, Chief Executive Officer and Chairman, will examine the key projects right now in progress driving the organization methodology; Jim Scibetta, President, will give a business and assembling outline; lastly, Charlie Reinhart, Chief Financial Officer, will give a recap of Q3 2016 money related results and any related upgrades before we open up the lines for inquiries.
Before I turn the bring over to the administration group, I might want to advise you that specific comments made by administration amid this call about the organization's future desires, arrangements, viewpoint and prospects and proclamations containing the words accepts, envisions, arranges, expects and comparative expressions constitute forward-glimpsed articulations inside the significance of the Private Securities Litigation Reform Act of 1995.
Any such forward-looking articulations depend on suspicions that the organization accepts are sensible and that are liable to an extensive variety of dangers and instabilities. Genuine results may contrast physically from those communicated or inferred by such forward-looking explanations. Huge numbers of these and different dangers and instabilities are portrayed in the Risk Factors segment of the organization's latest Annual Report on Form 10-K for the monetary year finished December 31, 2015 and in different filings with the SEC, which are accessible through the Investors and Media area of the Pacira site at www.pacira.com or on the SEC site at www.sec.gov.
Over the span of this call, we will likewise allude to certain non-GAAP money related measures. Meanings of these non-GAAP money related measures and compromises of these non-GAAP monetary measures to the most straightforwardly practically identical GAAP budgetary measures are incorporated into the income official statement for the quarter.
What's more, with that, we'll hear first from Dave.
David M. Stack - Pacira Pharmaceuticals, Inc.
Much appreciated, Jess. The superseding mission driving Pacira is to be the impetus for opioid minimization and in the long run opioid pre-surgery in America and past. In my comments today, we examine that we are making gigantic steps towards this mission. In any case, let me begin the call by recognizing that disregarding proceeded with development, EXPAREL deals have not quickened as quick as we had expected after the FDA determination in December 2015. It is taking us longer to turn around the aftermath from the notice letter, however changing the way prescription is drilled requires some investment, even with the tailwind of the opioid scourge.
We have a three-section procedure to quicken deals by making EXPAREL accessible to however many patients as could be allowed: one, to work with patients notwithstanding healing facility frameworks and doctor gatherings to institutionalize and widen the compass of opioid-saving conventions with EXPAREL through our advertising endeavors, upgraded recuperation conventions and instruction and preparing programs; second, is to work out strong clinical information to bolster commercial center utilization of EXPAREL for present and extended utilize; and three, is to underwrite in business associations for EXPAREL openings both in and outside the United States.
Q3 2016 Earnings Call
November 02, 2016 9:00 am ET
Administrators
Jessica Cho - Pacira Pharmaceuticals, Inc.
David M. Stack - Pacira Pharmaceuticals, Inc.
James S. Scibetta - Pacira Pharmaceuticals, Inc.
Charles A. Reinhart - Pacira Pharmaceuticals, Inc.
Scott N. Braunstein - Pacira Pharmaceuticals, Inc.
Investigators
David A. Amsellem - Piper Jaffray and Co.
Donald Bruce Ellis - JMP Securities LLC
Douglas Tsao - Barclays Capital, Inc.
Administrator
Much obliged to you for joining the Pacira Pharmaceuticals Third Quarter 2016 Financial Results Conference Call. Right now, all members are in a listen-just mode. Taking after the formal comments, the Pacira administration group will open the lines for a question-and-answer period. If you don't mind be exhorted that this call is being recorded at the organization's demand and will be filed on the organization's site for two weeks from today's date.
As of now, I might want to present Jessica Cho of Pacira Pharmaceuticals. Ma'am, you may start.
Jessica Cho - Pacira Pharmaceuticals, Inc.
Hello, everybody. The configuration of this call will be as per the following: Dave Stack, Chief Executive Officer and Chairman, will examine the key projects right now in progress driving the organization methodology; Jim Scibetta, President, will give a business and assembling outline; lastly, Charlie Reinhart, Chief Financial Officer, will give a recap of Q3 2016 money related results and any related upgrades before we open up the lines for inquiries.
Before I turn the bring over to the administration group, I might want to advise you that specific comments made by administration amid this call about the organization's future desires, arrangements, viewpoint and prospects and proclamations containing the words accepts, envisions, arranges, expects and comparative expressions constitute forward-glimpsed articulations inside the significance of the Private Securities Litigation Reform Act of 1995.
Any such forward-looking articulations depend on suspicions that the organization accepts are sensible and that are liable to an extensive variety of dangers and instabilities. Genuine results may contrast physically from those communicated or inferred by such forward-looking explanations. Huge numbers of these and different dangers and instabilities are portrayed in the Risk Factors segment of the organization's latest Annual Report on Form 10-K for the monetary year finished December 31, 2015 and in different filings with the SEC, which are accessible through the Investors and Media area of the Pacira site at www.pacira.com or on the SEC site at www.sec.gov.
Over the span of this call, we will likewise allude to certain non-GAAP money related measures. Meanings of these non-GAAP money related measures and compromises of these non-GAAP monetary measures to the most straightforwardly practically identical GAAP budgetary measures are incorporated into the income official statement for the quarter.
What's more, with that, we'll hear first from Dave.
David M. Stack - Pacira Pharmaceuticals, Inc.
Much appreciated, Jess. The superseding mission driving Pacira is to be the impetus for opioid minimization and in the long run opioid pre-surgery in America and past. In my comments today, we examine that we are making gigantic steps towards this mission. In any case, let me begin the call by recognizing that disregarding proceeded with development, EXPAREL deals have not quickened as quick as we had expected after the FDA determination in December 2015. It is taking us longer to turn around the aftermath from the notice letter, however changing the way prescription is drilled requires some investment, even with the tailwind of the opioid scourge.
We have a three-section procedure to quicken deals by making EXPAREL accessible to however many patients as could be allowed: one, to work with patients notwithstanding healing facility frameworks and doctor gatherings to institutionalize and widen the compass of opioid-saving conventions with EXPAREL through our advertising endeavors, upgraded recuperation conventions and instruction and preparing programs; second, is to work out strong clinical information to bolster commercial center utilization of EXPAREL for present and extended utilize; and three, is to underwrite in business associations for EXPAREL openings both in and outside the United States.
No comments:
Post a Comment
Note: only a member of this blog may post a comment.